JPMorgan Chase & Co. reissued their neutral rating on shares of Novartis (NYSE:NVS) in a research report released on Thursday morning.

Other equities research analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Novartis from a buy rating to a hold rating in a report on Friday, October 6th. Leerink Swann upped their target price on shares of Novartis from $89.00 to $91.00 and gave the stock a market perform rating in a report on Monday, October 23rd. Nord/LB restated a neutral rating on shares of Novartis in a report on Tuesday, January 2nd. UBS Group restated a neutral rating on shares of Novartis in a report on Monday, January 15th. Finally, Bank of America lowered shares of Novartis from a neutral rating to an underperform rating in a report on Wednesday, December 6th. Five investment analysts have rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the stock. Novartis currently has a consensus rating of Hold and a consensus price target of $85.32.

Shares of Novartis (NYSE:NVS) traded up $0.53 during midday trading on Thursday, hitting $86.94. 770,420 shares of the stock traded hands, compared to its average volume of 801,800. Novartis has a 52-week low of $69.53 and a 52-week high of $87.29. The firm has a market capitalization of $204,411.06, a price-to-earnings ratio of 30.94, a P/E/G ratio of 2.31 and a beta of 0.73. The company has a quick ratio of 0.81, a current ratio of 1.08 and a debt-to-equity ratio of 0.32.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.25 by $0.04. Novartis had a net margin of 13.73% and a return on equity of 15.77%. The firm had revenue of $12.41 billion for the quarter, compared to analyst estimates of $12.21 billion. During the same quarter in the prior year, the business earned $1.23 earnings per share. The business’s quarterly revenue was up 2.4% compared to the same quarter last year. sell-side analysts forecast that Novartis will post 4.79 earnings per share for the current fiscal year.

Hedge funds have recently modified their holdings of the business. Cetera Investment Advisers bought a new stake in Novartis in the 2nd quarter worth about $241,000. Bartlett & Co. LLC grew its position in Novartis by 1.6% in the 3rd quarter. Bartlett & Co. LLC now owns 473,081 shares of the company’s stock worth $40,614,000 after purchasing an additional 7,249 shares in the last quarter. Capital Bank & Trust Co grew its position in Novartis by 5.5% in the 3rd quarter. Capital Bank & Trust Co now owns 138,207 shares of the company’s stock worth $11,865,000 after purchasing an additional 7,201 shares in the last quarter. Atlantic Trust Group LLC grew its position in Novartis by 54.2% in the 3rd quarter. Atlantic Trust Group LLC now owns 72,427 shares of the company’s stock worth $6,218,000 after purchasing an additional 25,452 shares in the last quarter. Finally, Cedar Hill Associates LLC bought a new stake in Novartis in the 3rd quarter worth about $248,000. 10.85% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “JPMorgan Chase & Co. Reiterates “Neutral” Rating for Novartis (NVS)” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://theolympiareport.com/2018/01/20/jpmorgan-chase-co-reiterates-neutral-rating-for-novartis-nvs.html.

Novartis Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.